A plain language summary looking at nivolumab + chemotherapy for Asian people with advanced/recurrent stomach or gastroesophageal cancer

This Plain Language Summary of Publication article (PLSP) from Future Oncology explains the ATTRACTION-4 study. Researchers wanted to know whether adding a medication called nivolumab to chemotherapy could help people with advanced or recurrent stomach or gastroesophageal junction cancer better than standard chemotherapy alone.

Visit the site using this link to read the article.

This PLSP is based on two articles:

• ‘Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated,unresectable advanced or recurrent gastric or gastroesophageal junction cancer (ATTRACTION-4): a randomised, multicentre,double-blind, placebo-controlled, phase 3 trial’ published in The Lancet Oncology.
• ‘‘Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial’ published in Gastric Cancer.

Visit The Lancet using the link to read the original article.

Visit Springer Nature Link using the link to read the original article.

• chemotherapy
• Esophagogastric Junction
• First-line
• Gastric cancer
• nivolumab
• plain language summary